In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period ; day:22 ; month:8 ; year:2023 ; pages:1-13
Drugs in R & D ; (22.8.2023), 1-13
- Creator
-
Tak, Minji
Jeong, Hawon
Yun, Jihoon
Kim, Jihyun
Kim, Soyeon
Lee, Yoonsook
Park, Su Jin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-023-00433-7
- URN
-
urn:nbn:de:101:1-2023110608233288228855
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tak, Minji
- Jeong, Hawon
- Yun, Jihoon
- Kim, Jihyun
- Kim, Soyeon
- Lee, Yoonsook
- Park, Su Jin
- SpringerLink (Online service)
Other Objects (12)
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Meropenem: continuous or extended infusion?
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Physicochemical stability of Cabazitaxel Zentiva ® solution in vials after opening and diluted solutions in three infusion bags
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Nonexponential relaxation of diluted antiferromagnets
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Meropenem: continuous or extended infusion?
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Physicochemical stability of Cabazitaxel Zentiva ® solution in vials after opening and diluted solutions in three infusion bags
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Nonexponential relaxation of diluted antiferromagnets
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
Meropenem: continuous or extended infusion?
Treating C3 glomerulopathy with eculizumab
Treating C3 glomerulopathy with eculizumab
Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Physicochemical stability of Cabazitaxel Zentiva ® solution in vials after opening and diluted solutions in three infusion bags
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar